Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Ming-Chien Hung manages a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently has 1 pending office action. This action is being handled by 1 distinct examiner, ARNOLD, ERNST V, who is the busiest examiner with 1 pending office action. The prosecution is concentrated in 1 distinct art unit, indicating a specific technical focus.
The data shows that the portfolio's current USPTO activity is very limited, with 1 distinct examiner and 1 distinct art unit. For a practitioner, this means that the 1 pending office action is the only active matter requiring attention. ARNOLD, ERNST V is the only examiner the portfolio is currently interacting with, which allows for a very focused prosecution strategy. The 1 distinct art unit suggests that the pending application is in a specific area of Biotechnology & Pharmaceuticals.
Because there is only 1 pending office action, the portfolio's immediate progress is entirely dependent on the resolution of this one matter. This concentration simplifies the management of the portfolio but also means that the entire active portfolio is subject to the examination of a single individual. The busiest examiner, ARNOLD, ERNST V, is responsible for the 1 pending office action. Practitioners should focus on the specific examination history of ARNOLD, ERNST V to optimize the response. This centralized approach requires high precision in the single active matter to ensure the portfolio's growth.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ARNOLD, ERNST V | 1 | 48.2% | +12.9% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17335124 | Pharmaceutical Composition for Improving Respiratory Damage and Use for Manufacturing Pharmaceutical Composition for Improving Respiratory Damage | ARNOLD, ERNST V | — |
| Art Unit | Apps |
|---|---|
| 1613 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17335124 | Pharmaceutical Composition for Improving Respiratory Damage and Use for Manufacturing Pharmaceutical Composition for Improving Respiratory Damage | ARNOLD, ERNST V | 1613 | §103Other | Non-Final OA | — | Pending | Jun 01, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial